Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

Supplements And Featured PublicationsEmerging Treatments and Clinical Challenges in Myelodysplastic Syndromes: ASCO 2021 and EHA 2021 Updates
Volume 1
Issue 1

In Partnership With:

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome (HR-MDS).

Findings from the randomized, proof-of-concept phase 2 study (NCT02610777) demonstrated a clinically meaningful improvement in overall survival and event-free survival with the combination of pevonedistat plus azacitidine vs azacitidine alone in patients with HR-MDS/chronic myelomonocytic leukemia or low-blast acute myeloid leukemia, Sallman says.

The overall response rate (ORR) was 70.9% with pevonedistat/azacitidine vs 60.4% with azacitidine alone in the overall patient population. The ORR was 79.3% vs 56.7%, respectively, for patients with HR-MDS. The median duration of response was 34.6 months compared with 13.1 months, respectively, in patients with HR-MDS, Sallman concludes.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Expert on AML
Expert on AML
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Related Content